TrialAnnals of the rheumatic diseases2017

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.

Jung-Yoon Choe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.